1-11 of 11 results for subject:Retinoblastoma
Librarians' tools
- Search time
- 0.232 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Retinoblastoma
- We searched for
- subject_t:Retinoblastoma OR subject_ses:456648
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Science, Innovation and Technology, how much Government investment into retinoblastoma research was in 2023-24; and which public bodies provided that investment.
To ask the Secretary of State for Science, Innovation and Technology, how much Government investment into retinoblastoma research was in 2023-24; and which public bodies provided that investment.
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
open-angle glaucoma | NIHR allocated £140,000 for open-angle Glaucoma research in 2023-24 | The total commitment across UKRI in 2023-24 for glaucoma research was £1,209,175 for 3 awards (1 award from Innovate UK; 2 awards from MRC). |
closed-angle glaucoma | NIHR did not commit any specific funding for closed-angle glaucoma research during the financial year of 2023-24. | |
wet macular degeneration | NIHR did not commit any specific funding for wet macular degeneration research during the financial year of 2023-24. | The total commitment across UKRI in 2023-24 for macular degeneration research was £3,941,644 for 11 awards (1 award from BBSRC; 3 awards from EPSRC; 1 award from Innovate UK; 3 awards from MRC; 2 awards from centrally managed UKRI schemes). |
dry macular degeneration | NIHR did not commit any specific funing for dry macular degeneration research during the financial year of 2023-24. | |
diabetic retinopathy | NIHR allocated £977,340 for diabetic retinopathy research in the financial year 2023-24. | The total commitment across UKRI in 2023-24 for diabetic retinopathy research was £1,068,246 for 2 awards (1 award from Innovate UK; 1 award from EPSRC). |
retinitis pigmentosa | NIHR did not commit any specific funding for retinitis pigmentosa research during financial year 2023-24. | UKRI did not commit any specific funding for retinitis pigmentosa research in 2023-24. |
retinoblastoma | NIHR did not commit any specific funding for retinoblastoma research during the financial year of 2023-24 | UKRI did not commit any specific funding for retinoblastoma research in 2023-24. |
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that GPs are trained to identify retinoblastoma in young children.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that GPs are trained to identify retinoblastoma in young children.
Each individual medical school sets its own undergraduate medical curriculum. These have to meet the standards set by the General Medical Council (GMC), who then monitor and check to make sure that these standards are maintained.
The curricula for postgraduate specialty training is set by individual royal colleges and faculties, and the GMC approves curricula and assessment systems for each training programme. Training curricula for doctors emphasise the skills and approaches that a doctor must develop in order to ensure accurate and timely diagnoses and treatment plans for their patients. The Royal College of General Practitioners sets the curriculum for general practitioners (GPs). In order to demonstrate the core competences in the care of children and young people, the curriculum sets out that GPs should be aware of the early presenting symptoms of childhood cancers and possible differentials, such as retinoblastoma.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that optometrists are trained to identify retinoblastoma at an early stage in young children.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that optometrists are trained to identify retinoblastoma at an early stage in young children.
Each individual medical school sets its own undergraduate medical curriculum. These have to meet the standards set by the General Medical Council (GMC), who then monitor and check to make sure that these standards are maintained.
The curricula for postgraduate specialty training is set by individual royal colleges and faculties, and the GMC approves curricula and assessment systems for each training programme. Training curricula for doctors emphasise the skills and approaches that a doctor must develop in order to ensure accurate and timely diagnoses and treatment plans for their patients. The Royal College of General Practitioners sets the curriculum for general practitioners (GPs). In order to demonstrate the core competences in the care of children and young people, the curriculum sets out that GPs should be aware of the early presenting symptoms of childhood cancers and possible differentials, such as retinoblastoma.
To ask the Secretary of State for Health what steps his Department is taking to raise awareness of retinoblastoma.
[113876]
To ask the Secretary of State for Health what steps his Department is taking to raise awareness of retinoblastoma.
[113876]
Since 2005, ‘Improving outcomes for children and young people with cancer’, published by the National Institute for Health and Clinical Excellence (NICE), has supported trusts in planning, commissioning and organising services for children and young people with cancer, including retinoblastoma. One of its recommendations is the establishment of support for professionals in primary and secondary care in the recognition and referral of suspected cancer in children and young people.
This guidance is complemented by ‘Referral for suspected cancer’, also published by the NICE in 2005, which sets out best practice advice on referral for suspected cancer in adults and children. The guidance covers a wide
range of cancers, including retinoblastoma, and identifies key symptoms and evidence to consider when referring a patient for suspected cancer.
These sets of guidance are continuing to support the commissioning of quality services for children and young people with cancer in the reformed national health service.
During 2011, departmental officials met two charities for children and young people cancer, with the aim of identifying some of the barriers to early diagnosis and to discuss potential solutions. This work has been fed into the National Awareness and Early Diagnosis Initiative and will inform future activity in this area.
To ask the Secretary of State for Health what steps his Department is taking to improve early diagnosis of retinoblastoma in children.
To ask the Secretary of State for Health what steps his Department is taking to improve early diagnosis of retinoblastoma in children.
To ask the Secretary of State for Health what recent studies his Department has commissioned into retinoblastoma; and if he will make a statement.
To ask the Secretary of State for Health what recent studies his Department has commissioned into retinoblastoma; and if he will make a statement.
To ask the Secretary of State for Health what assessment he has made of the number of people diagnosed with retinoblastoma in (a) Medway Primary Care Trust, (b) West Kent Primary Care Trust, (c) Kent and (d) England in each of the last five years.
To ask the Secretary of State for Health what assessment he has made of the number of people diagnosed with retinoblastoma in (a) Medway Primary Care Trust, (b) West Kent Primary Care Trust, (c) Kent and (d) England in each of the last five years.
| Table 1. Number of newly diagnosed cases of retinoblastoma, England, Kent and Medway primary care trust, 2005-09¹, ², ³, 4 | ||||||
|---|---|---|---|---|---|---|
| Registrations (persons) | ||||||
| 2005 | 2006 | 2007 | 2008 | 2009 | Total | |
| England | 36 | 46 | 44 | 48 | 51 | 225 |
| Kent | * | * | * | * | * | 5 |
| Medway PCT | * | * | * | * | * | 3 |
| ¹ Retinoblastoma is coded as C69.2 in the International Classification of Diseases, tenth revision (ICD-10). | ||||||
| ² Figures are based on boundaries as of February 2012 and exclude non-residents. | ||||||
| ³ Newly diagnosed cancers registered in each calendar year. | ||||||
| 4 Numbers under three have been suppressed, so potentially identifiable data are not revealed. A cell which has been suppressed for disclosure control is denoted by '*'. | ||||||
| Source: | ||||||
| Office for National Statistics |
To ask the Secretary of State for Health, if he will take steps to encourage more regular and thorough eye tests for children to check for cancers, with particular reference to retinoblastoma. - Including figures.
To ask the Secretary of State for Health, if he will take steps to encourage more regular and thorough eye tests for children to check for cancers, with particular reference to retinoblastoma. - Including figures.
To ask the Secretary of State for Health, what drugs are being used and being tested in the treatment of (a) childhood acute lymphoblastic leukaemia, (b) acute myelogenous leukemia, (c) chronic lymphocytic leukemia, (d) esophageal cancer, (e) osteosarcoma, (f) pancreatic cancer, (g) retinoblastoma, (h) sarcoma, (i) stomach cancer, (j) thyroid...
To ask the Secretary of State for Health, what drugs are being used and being tested in the treatment of (a) childhood acute lymphoblastic leukaemia, (b) acute myelogenous leukemia, (c) chronic lymphocytic leukemia, (d) esophageal cancer, (e) osteosarcoma, (f) pancreatic cancer, (g) retinoblastoma, (h) sarcoma, (i) stomach cancer, (j) thyroid...
To ask Mr Chancellor of the Exchequer, what the latest survival rate is for those suffering from (a) childhood acute lymphoblastic leukaemia, (b) acute myelogenous leukaemia, (c) chronic lymphocytic leukaemia, (d) esophageal cancer, (e) osteosarcoma, (f) pancreatic cancer, (g) retinoblastoma, (h) sarcoma, (i) stomach cancer, (j) thyroid cancer and (k)...
To ask Mr Chancellor of the Exchequer, what the latest survival rate is for those suffering from (a) childhood acute lymphoblastic leukaemia, (b) acute myelogenous leukaemia, (c) chronic lymphocytic leukaemia, (d) esophageal cancer, (e) osteosarcoma, (f) pancreatic cancer, (g) retinoblastoma, (h) sarcoma, (i) stomach cancer, (j) thyroid cancer and (k)...
To ask Mr Chancellor of the Exchequer, how many new cases of (a) acute myelogenous leukaemia, (b) chronic lymphocytic leukaemia, (c) oesophageal cancer, (d) osteosarcoma, (e) pancreatic cancer, (f) retinoblastoma, (g) sarcoma, (h) stomach cancer, (i) thyroid cancer and (j) Waldenstrom's Macroglobulinemia have been recorded in each of the last...
To ask Mr Chancellor of the Exchequer, how many new cases of (a) acute myelogenous leukaemia, (b) chronic lymphocytic leukaemia, (c) oesophageal cancer, (d) osteosarcoma, (e) pancreatic cancer, (f) retinoblastoma, (g) sarcoma, (h) stomach cancer, (i) thyroid cancer and (j) Waldenstrom's Macroglobulinemia have been recorded in each of the last...